Search - tctmd.com

Displaying 1 - 20 of 250

Sort: Relevancy | Date

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

2016 DAPT Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Adnan K. Chhatriwalla

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

Presentation TCT 2016

Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies

Presenter: George D. Dangas, Debabrata Mukherjee, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Deciding on the Duration of DAPT

Presenter: George D. Dangas, Debabrata Mukherjee, Neal S. Kleiman

November 01, 2016

Presentation TCT 2016

TCT 56: Validation of PARIS Risk Scores in a Large Multi-Ethnic PCI Cohort: Results From a Large Single-Center Registry

Presenter: Neal S. Kleiman, David F. Kong, Usman Baber

October 31, 2016

Presentation TCT 2016

TCT 55: RiskBenefit Analysis of Upstream Antithrombotic Therapy in Patients With NonST-Segment Elevation Acute Coronary Syndromes Prior to Coronary Angiography

Presenter: Neal S. Kleiman, David F. Kong, Bjorn Redfors

October 31, 2016

Presentation TCT 2016

TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial

Presenter: Neal S. Kleiman, David F. Kong, Didier Carrié

October 31, 2016

Presentation TCT 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield

October 31, 2016

Presentation TCT 2016

TCT 7: Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Bjorn Redfors

October 31, 2016

Presentation TCT 2016

TCT 8: Impact of Aspirin Resistance on Outcomes After Coronary Events

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Christine Chung

October 31, 2016

Presentation TCT 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber

October 31, 2016

Presentation TCT 2016

TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Ramin Ebrahimi

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Presenter: John A. Bittl, Daniel I. Simon, Eric Van Belle

October 30, 2016

Presentation TCT 2016

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Presenter: John A. Bittl, Daniel I. Simon, Tullio Palmerini

October 30, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation TCT 2016

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Presenter: John A. Bittl, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Presenter: John A. Bittl, Daniel I. Simon, Robert W. Yeh

October 30, 2016

Advertisement

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

2016 DAPT Update: Evidence and Guidelines

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies

Deciding on the Duration of DAPT

TCT 56: Validation of PARIS Risk Scores in a Large Multi-Ethnic PCI Cohort: Results From a Large Single-Center Registry

TCT 55: RiskBenefit Analysis of Upstream Antithrombotic Therapy in Patients With NonST-Segment Elevation Acute Coronary Syndromes Prior to Coronary Angiography

TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

TCT 7: Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES

TCT 8: Impact of Aspirin Resistance on Outcomes After Coronary Events

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content